Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Gastrointestinal Cancers
•
Medical Oncology
In a patient with metastatic gastric cancer with high PDL-1 CPS score (10), at what point, if any, would you consider omitting chemotherapy and continuing immunotherapy alone based on CHECKMATE 649 if patient has a favorable or complete response?
Related Questions
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
Would you ever consider foregoing surveillance CT scans for resected stage II or III colon cancer in favor of circulating ctDNA assays?
Is there data to support the upfront use of encorafenib and cetuximab in metastatic BRAF V600E-mutated right-sided colon cancer?
How does the management of POLE mutated colorectal cancer differ from that of dMMR/MSI high disease?
Which patients with localized esophageal adenocarcinoma, if any, would you offer nivolumab after lack of pCR to neoadjuvant FLOT?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
Would you ever consider using durvalumab/tremelimumab in second line after progression on Atezolizumab and Bevacizumab in advanced HCC?
What is your preferred way of administering nivolumab/ipilimumab in GI cancers?
How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?
How do you approach patients with partially occlusive thrombus in the splenic vein posterior to the pancreatic cancer lesion?
